DiaCarta Named to MedTech Outlook’s Top 10 In-Vitro Diagnostic Technology Solution Providers 2018

by DiaCarta Inc. | Jul 31, 2018 | Press Releases

DiaCarta has been recognized as one of the Top 10 In-Vitro Diagnostic Technology Solution Providers 2018 by Med Tech Outlook Magazine. The positioning is based on an evaluation of DiaCarta’s specialty in genomic testing for biomarkers, personalized diagnostics and clinical sample testing service provided in their CLIA-certified lab. The award list is selected by a panel of experts and members of MedTech Outlook’s editorial board to recognize and promote advanced in-vitro diagnostic technology that creates an immense impact in the U.S. market and dedicating its steadfastness to create a big difference in this continuously evolving arena.

“We take pride in honoring DiaCarta as one among the top 10 companies that are specialized in providing In-Vitro Diagnostic Solution. We value DiaCarta’s XNA technology which enables ultra-sensitive detection of actionable mutations using qPCR, next-generation sequencing (NGS) and other platforms for liquid biopsy, FFPE and other traditionally challenging specimens,” said Alex D’souza, Managing Editor of MedTech Outlook.

“We are honored to be selected by MedTech Outlook,” said Aiguo (Adam) Zhang, CEO and Founder of DiaCarta, “It helps further validate and reaffirm our strategic and technical goals to provide highly sensitive and advanced technologies to redefine the way molecular diagnostics and translational genomics impact health care treatment plans.”

ABOUT DIACARTA

DiaCarta is a translational genomics and personalized diagnostics company based in Richmond, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. With over 20,000 square feet dedicated to a GMP-compliant lab space as well as CLIA and ISO 13485 certifications, DiaCarta is changing the landscape of molecular diagnostics.

ABOUT MEDTECH OUTLOOK

Published from Fremont, California, MedTech Outlook is a print magazine that covers most important and latest developments in the health care industry. Medical Tech Outlook magazine is a bright, interactive and powerful platform incubating the facts and insights from the medical device industry. All the latest updates, market insights and technological developments from the industry are presented to our elite and affluent group of readers to comprehend essential developments towards the use of wearable technology as it continues to carve out its space within mainstream healthcare.

FDA Report: DiaCarta COVID-19 Tests Rank Top 3 Among FDA SARS-CoV-2 Reference Panel Tests

Oct 6, 2020 | Press Releases

According to the recent FDA SARS-CoV-2 Reference Panel Comparative Data released on September 15, among all the FDA EUA tests with returned results, DiaCarta’s QuantiVirusTM SARS-CoV-2 Test and QuantiVirus™ SARS-CoV-2 Multiplex Test both rank within the top 3 for product sensitivity.

DiaCarta’s COVID-19 Test Ranks Top 10 Among All FDA EUA Tests Based on Limit of Detection

Sep 14, 2020 | Press Releases

DiaCarta’s QuantiVirus™ SARS-CoV-2 Multiplex Test ranks among the top 10 kits in terms of low limit of detection (LoD). DiaCarta is the top 6 company, after Perkin Elmer, Roche, Quest, RTA and BD Biosciences.

DiaCarta Receives Regulatory COFEPRIS Approval in Mexico & ICMR Approval in India for its FDA EUA Approved QuantiVirus™ SARS-CoV-2 Test

Jul 15, 2020 | Press Releases

DiaCarta Inc., a precision molecular diagnostics company with a unique, patented XNA technology platform for the development of novel liquid biopsy tests, announced today that its QuantiVirus™ SARS-CoV-2 test has been approved for distribution in Mexico.

DiaCarta SARS-CoV-2 Test Detecting 3 Viral Genes Receives US FDA Emergency Use Authorization & Test Manufacturing Expanded to 500K COVID-19 Tests/Week

Apr 13, 2020 | Press Releases

DiaCarta Inc, a precision molecular diagnostic company in CA, announced Thursday the US FDA granted Emergency Use Authorization for DiaCarta’s proprietary QuantiVirus™ PCR diagnostic (Dx) test specifically detecting three different genes of SARS-CoV-2, the virus causing the COVID-19 pandemic. DiaCarta recently expanded manufacturing capacity to 500,000 tests per week and is planning to expand to even larger (4x) scale manufacturing to meet the increasing demand for PCR tests to monitor COVID-19.

DiaCarta Inc. has filed for EUA with the FDA and has received CE mark for its highly sensitive QuantiVirus™ SARS-CoV-2 Test Kit

Mar 25, 2020 | Press Releases

DiaCarta Inc., a precision molecular diagnostic company, announced today that it has filed for Emergency Use Authorization (EUA) with the US FDA for its QuantiVirus™ SARS-CoV-2 test and has validated the COVID-19 diagnostic test in its own CLIA certified lab in Richmond, CA to provide testing services for healthcare providers and patients. DiaCarta recently received Conformitè Europëenne (CE) Mark for its product.

Press release